Issues

Home > Issues (Page 25)

May 21, 2020 Issues, Price and Costs

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text css=".vc_custom_1590107672986{padding-right: 40px !important;}"]DOWNLOAD THE PDF In October 2019, the Center for Medical Economics and Innovation at the Pacific Research Institute, under the direction of Dr. Wayne Winegarden, released its second study documenting the savings potential enabled by biosimilars. Biosimilars are medicines manufactured in, or derived from, biological sources that are developed to be similar to FDA-approved reference products. Biosimilars are only approved to compete in nine biologic drug classes in the U.S....

May 20, 2020 Coronavirus, Innovation

A COVID-19 Vaccine by January? Here’s Why It’s Possible But Not Likely By Christopher Curley The timeline to develop a safe, effective vaccine to fight a virus is typically counted in years — or even decades. But with the COVID-19 pandemic affecting millions around the world and killing hundreds of thousands of people, the race is on to produce a vaccine faster than ever before. President Donald Trump has said a vaccine could be available by January, which would be an unprecedented development cycle. But how realistic is that? Experts...

May 19, 2020 Coronavirus

As the COVID-19 epidemic drags on with no end in sight, the U.S. economy in tatters, and “reopening” going haltingly, many observers have come to the realization that we might need to learn to “live with the virus”—meaning with ongoing new infections—until a vaccine is available. Expecting a coronavirus vaccine in the near future may be the triumph of hope over experience. Thus, there is an understandable hunger for one, and some 95 vaccines to prevent COVID-19 are now in various stages...

May 18, 2020 Blog, Coronavirus

It is expected that any day now, the White House will release an executive order requiring certain drugs to be manufactured in the United States. It's part of a wider push by both the administration and Congress to force the federal government to buy more American-made goods and reduce reliance on countries like China. This push is misguided. The administration's "Buy America" agenda would derail our response to COVID-19 and could have long-lasting negative consequences for our economy. The best way to maintain efficient, high-quality production of drugs and other medical equipment is...

May 18, 2020 Blog, Coronavirus

On a recent episode of CNN's "Fareed Zakaria GPS," White House adviser and trade hawk Peter Navarro observed that the Chinese government had not been forthcoming from the get-go about the potential for COVID-19 to become a global pandemic. He postulated that the original spread of the virus could have been blocked and the pandemic contained completely – if China had really wanted that to happen. Navarro went on to suggest that the virus originated from a bioweapons lab, and...

May 15, 2020 Innovation, Issues

Medical innovations do not happen overnight. Whether it is gene therapies, new vaccines, or cutting-edge medical equipment, developing innovative medical products is a risky venture. It also takes time, lots of financial resources, and most importantly, human ingenuity. Developing new drugs, for instance, can take between 10 and 15 years. Now, more than ever, it is imperative that our regulatory framework encourages innovation and protects the intellectual property that makes innovation possible. Otherwise, the medical advancements we desperately need will cease....

May 12, 2020 Blog, Coronavirus

Perhaps not since the Second World War has there been so much fear, anxiety, misery, and grief in this country. Many people are finding some measure of comfort by turning inward and using what amounts to a biological trick. How many times have you heard someone say to a person who is angry and agitated, “Hey, take a few deep breaths and chill.” Well, it works, and the reason has a physiological explanation. As does the popularity of the “mindfulness” phenomenon, which...

May 11, 2020 Coronavirus, Issues, Price and Costs, Value

There they go again. In the midst of the race for an effective COVID-19 treatment the Institute for Clinical and Economic Review (ICER) has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong. Remdesivir, produced by Gilead Sciences Inc., is an experimental antiviral medication that did not work as hoped to treat Hepatitis C, but is showing promise as a treatment for viruses such as SARS and COVID-19. If ICER’s analysis were...

May 11, 2020 Blog, Coronavirus

While many heroic doctors, nurses and other health care professionals are working long hours and risking their lives to treat COVID-19 patients, others have seen their workloads and hospital occupancy rates drop dramatically as a result of the coronavirus pandemic. This has created a financial crisis and endangered public health. At the onset of the COVID-19 outbreak, public health officials urged hospitals to suspend non-essential medical procedures. U.S. hospitals canceled tens of thousands of elective surgeries and other procedures, and urged...

May 8, 2020 Blog, Issues, Policy Proposals

It was not long ago that the economy’s rising tide was supporting state budgets across the country. As the Pew Charitable Trusts noted, widespread economic prosperity was supporting tax revenue growth and creating budget surpluses. When times are good, saving money is not always a priority in state capitols. But, times are no longer good, and saving money is now a top policy priority. The carnage is not contained to state budgets either. Businesses large and small are losing money, families are struggling...

May 1, 2020 Blog, Coronavirus

By Andrew I. Fillat and Henry I. Miller The headline, of course, is an aphorism dating from 1862 that was popularized by the charming 1992 Tom Hanks film, “Forrest Gump.” Stupid may be an innate characteristic, but dumbness is certainly an opportunity available to all. It can be especially surprising and sometimes infuriating when a person not thought to be stupid does some really dumb things. Back in college at our fraternity, we had an “award” for pledges who said or did dumb...

April 30, 2020 Blog, Coronavirus

Forcing a restructuring of the current pharmaceutical supply chain is a terrible idea. Yet, as a recent Wall Street Journal editorial exemplifies, there is growing support for this ill-considered policy. And, these proposals are not simply mere academic musings. The Trump Administration may implement an Executive Order that would turn this idea into actual policy. Congress, not to be outdone, is also considering several proposals that would force federal agencies to purchase drugs and medical supplies exclusively from U.S. suppliers. If implemented, these “Buy...

April 28, 2020 Blog, Coronavirus, Policy Proposals

On ‘Supply-Chain Repatriation,’ It’s Buyer (and Nation) Beware By Scott Lincicome One of the most fashionable COVID-19 proposals being circulated by Washington politicians and pundits these days is the “repatriating” of global supply chains for pharmaceuticals, medical devices, and “personal protective equipment” that have been “outsourced” over the past three decades, leaving America utterly dependent on foreign countries, especially China, for these essential products. Bringing that manufacturing back home, so the story goes, is the only way to ensure future “resiliency” in...

April 28, 2020 Coronavirus, Policy Proposals, Radio

PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies Sally C. Pipes joins PRI's Next Round podcast to discuss some of the health care challenges that have popped up during the coronavirus crisis, including a renewed push for single-payer and calls for prescription drug price controls and a “Buy America” mandate for drug manufacturing. We also discuss a few positives changes that have occurred despite these tough times – the rise of telehealth and the rolling back...

April 27, 2020 Coronavirus, Policy Proposals, Radio

Dr. Henry Miller joins the nationally-syndicated Lars Larson Show to debate shelter-in-place rollbacks by states and European countries and why it could be too early. Miller and Larson also debate the approaches of other countries and how their infection and death rate compare to the United States. Dr. Miller's segment begins at the 47:00 minute mark.  Lars Larson National Podcast · Lars Larson National Podcast 04-21-20...

April 27, 2020 Blog, Coronavirus, Policy Proposals

The presidential campaign of Sen. Bernie Sanders, I-Vt., may have ended, but his "Medicare-for-all" crusade marches on. Writing in The New York Times last week, Sanders argued that the coronavirus outbreak proved the government should take over our nation's health care system. Sanders isn't the only one championing "Medicare-for-all" in the wake of the pandemic. More than half of voters now say they support a single-payer system. But "Medicare-for-all" would not have improved our nation's response to the outbreak. Other countries with socialized medicine have struggled mightily to combat COVID-19. In fact, the United States would have been even...

April 27, 2020 Blog, Coronavirus, Innovation

How hydroxychloroquine toes the line between promise and 'happy talk' in the coronavirus fight By: Anjalee Khemlani After weeks of polarizing debate over the use of two generic anti-malarial drugs, hydroxychloroquine and chloroquine, the Food and Drug Administration this week warned they were not “safe and effective” when used on COVID-19 patients. However, the hydroxychloroquine debate is far from over, as the drug gets qualified support from others deeply involved in the war against the coronavirus, and is used to treat COVID-19 patients...